安琪酵母(600298.SH):酶製劑公司擬對“年產5000噸新型酶製劑綠色製造項目”進行變更
格隆匯9月13日丨安琪酵母(600298.SH)公佈,為匹配酶製劑生產線現有的工藝設備技術,考慮到未來酶製劑產品市場需求可能出現快速增加和日後其餘生物製品的發展,公司控股子公司安琪酶製劑(宜昌)有限公司(簡稱:酶製劑公司)擬對募投項目年產5000噸新型酶製劑綠色製造項目進行變更,由原來規劃的新建年產3500噸酶製劑和搬遷年產1500噸酶製劑製造項目變更為全部新建實施年產5000噸酶製劑綠色製造項目,投資預算由3.3988億元變更為4.017億元,投資增加6182萬元。
此次項目變更僅對實施方案進行變更,主要是土建投資和設備投資發生變更,實施主體未發生變化,也未改變募集資金投資方向,不涉及募集資金金額的調整,不涉及募投項目使用募集資金金額的調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.